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Background: The single-center, open-label, four-arm, exploratory study investigates the relation of different
anti-diabetics to serum levels of active TGF-β, a known pro-fibrotic stimulus, before and after a defined test meal.
Findings: We investigated sera of patients with type 2 diabetes mellitus (T2DM) treated with metformin and
sulfonylurea, insulin glargine or a DPP-4 inhibitor (DPP4i). Patients’ sera were analyzed before and 5 h after a
defined test meal at intervals of 30 min.
The sulfonylurea/metformin group exhibited the highest basal levels of active TGF-β (31.50 ± 3.58 ng/ml). The
glargine/metformin group had active TGF-β levels (24.98 ± 1.90 ng/ml) that were comparable to those of the
healthy participants (22.12 ± 2.34 ng/ml). The lowest basal levels of active TGF-β were detected in the
DPP-4i/metformin group (12.28 ± 0.84 ng/ml). Following the intake of a standardized meal, active TGF-β levels
decreased (approx. 30%) in healthy subjects as well as in the sulfonylurea/metformin group and in the glargine/
metformin group. After 5 h, the active TGF-β levels were normalized to basal levels. Active TGF-β levels in the
DPP-4i/metformin group did not change significantly after the test meal. Overall plasma levels of insulin and
proinsulin were comparable between healthy participants, and T2DM patients in the glargin/metformin group
and in the DPP4i/metformin group. However, no correlation between active TGF-β levels, glucose, insulin or
pro-insulin levels was detected.
Conclusions: T2DM patients often exhibit elevated levels of pro-fibrotic active TGF-β. Our results suggest that
glargine/metformin and DPP4i/metformin treatment may more effectively reduce active TGF-β serum levels
than the sulfonylurea/metformin treatment.
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Diabetes mellitus type 2 (T2DM) is a chronic metabolic
disorder with a dramatically increasing prevalence [1].
T2DM stems from a progressive insulin secretory defect
on the background of insulin resistance [2]. Prolonged
insufficient metabolic control with constantly elevated
HbA1c levels inevitably leads to complications, most
commonly to diabetic nephropathy, diabetic retinopathy,
diabetic neuropathy, and macrovascular problems. TGF-
β1, a known pro-fibrotic factor, activates the production
of extracellular matrix by mesangial cells and interstitial
fibroblasts in the kidneys, and thus contributes to the* Correspondence: stefan.pscherer@kliniken-sob.de
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reproduction in any medium, provided the ormanifestation of diabetic kidney disease [3]. In mesangial
cells, it has been demonstrated that the expression and
activity of TGF-β1 are directly influenced by glucose
levels [4].
The aim of this study was investigating the influence of
different pharmacological strategies in Type 2 diabetics on
basal active TGF-β serum levels and active TGF-β serum
levels after a standardized test meal in correlation with in-
sulin, proinsulin and glucose levels as possible regulators.
Study groups
The first publication of this single-center, open-label,
four-arm, exploratory study investigated the influence of
different pharmacological strategies on the postprandial
processing of intact proinsulin in T2DM [5]. For the
present study, each group consisted of 20 participants
on average. Baseline demographics are shown in Table 1.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Study subjects
C S + M G + M D + M
Participants 20 21 20 19
Ratio male/female 12/8 16/5 15/5 11/8
Age [a] 65 ± 1.33 64 ± 1.5 65 ± 1.58 62 ± 1.92
Duration of diabetes [a] - 7.9 ± 0.9 8.7 ± 1.3 6.8 ± 0.9
BMI 27.1 ± 3.5 31.6 ± 2.9 30.8 ± 2.9 30.2 ± 3.3
HbA1c 5.6 ± 0.3 7.0 ± 0.5 7.2 ± 0.2 6.6 ± 0.4
Basal glucose [mg/dl] 100.1 ± 1.5 148.0 ± 3.9*** 146.0 ± 5.1*** 144.3 ± 5.1***
Basal insulin [pmol/l] 9.02 ± 0.87 17.23 ± 1.63*** 10.64 ± 1.59°° 11.70 ± 0.90°
Basal proinsulin [pmol/l] 5.26 ± 0.39 16.37 ± 1.45*** 9.378 ± 0.97*/°°° 6.878 ± 0.49°°°
***p < 0.001 as compared to healthy controls.
°p < 0.05 °°p < 0.01 °°°p < 0.001 as compared to “S+M” group.
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diabetes mellitus were excluded by an oral glucose toler-
ance test. T2DM patients had been treated with a con-
stant anti-diabetic dose according to the following
pharmacological strategies for at least 6 months:
 sulfonylurea plus metformin (S+M) for 6 to 12
months
 the long-acting insulin analogue glargine plus
metformin (G+M) for 6 to 12 months
 a DPP-4 inhibitor plus metformin (D+M) for the
past 6 months with a stable anti-diabetic dosage
during the past 3 months
Ethics statement
The study was performed according to the 1964 Dec-
laration of Helsinki. Written informed consent was
obtained from all patients. The study was approved by
an independent ethics committee (Ethik-Kommission der
Landesärztekammer Rheinland-Pfalz, Mainz, Germany)
and a regulatory authority (The Bundesinstitut für
Arzneimittel und Medizinprodukte, Bonn, Germany) [5].
Serum and plasma analysis
Plasma levels of TGF-β, insulin, proinsulin, and blood glu-
cose were measured after a fasting period and after a stan-
dardized meal for 5 hours. Plasma proinsulin and insulin
levels were measured with an enzyme-linked immuno-
sorbent assay [5]. Blood glucose levels were measured with
an electrochemical biosensor [5]. Serum levels of active
TGF-β were measured using TGF-β-reporter cells (MFB-
F11) as reported [6,7].Statistics
Statistics and data calculation were performed with the
GraphPad Prism software (La Jolla, USA). Results are
expressed as mean ± SEM. Sample distribution was ana-
lyzed with the D’Agostino & Pearson omnibus normalitytest. Data sets were compared by one-way analysis of
variance followed by Bonferroni’s multiple comparison
test. p < 0.05 was taken as the minimum level of
significance.
Results
Lowest basal (fasting) blood glucose levels were detected
in the control group. In all groups, blood glucose levels
increased after the standardized test meal. The peak was
reached after 30 to 60 min in the control group (~25%
increase), and after 60 to 90 min in the T2DM groups
(~50% increase). Blood glucose levels were normalized
to baseline levels faster in the control group (2 h) than
in all three T2DM groups (5 h) (Figure 1a).
Insulin plasma levels increased after the standardized
test meal. The peak was reached after 30–60 min in the
control group (~7-fold), and after 60–90 min in the
T2DM groups (5 to 6-fold). Plasma insulin levels were
normalized to baseline levels faster in the control group
(after 3 h) than in all T2DM groups (after 5 h) (Figure 1b).
The lowest basal plasma proinsulin levels were ob-
served in the control group, while the highest levels
were found in the T2DM patients treated with S+M. In
all groups, plasma proinsulin levels increased after the
standardized test meal. In the control group, the peak
was reached after 90–120 min (~3-fold increase), which
decreased to baseline levels after 5 h. In all three T2DM
groups, peak plasma proinsulin levels were observed
after 150 min. Plasma proinsulin levels in these groups
did not normalize to baseline levels within the observed
time frame (Figure 1c).
Healthy controls (22.12±2.34 ng/ml) and T2DM pa-
tients treated with G+M (24.98±1.90 ng/ml) had com-
parable basal (fasting) serum levels of active TGF-β.
While T2DM patients receiving S+M (31.50±3.58 ng/
ml) had significantly higher baseline (fasting) active
TGF-β serum levels, T2DM patients treated with D+M
exhibited significantly lower fasting active TGF-β serum
levels (12.28±0.84 ng/ml) (Figure 2a). Following a
proinsulin plasma levels



























































































Figure 1 Blood glucose, insulin and proinsulin levels after a test meal. T2DM patients treated with metformin and sulfonylurea (S+M),
insulin glargine (G+M) or a DPP-4 inhibitor (D+M) as well as non-diabetic controls (C) received a standardized test meal. Over the course of 5 h,
(a) blood glucose, (b) insulin, and (c) proinsulin levels were determined at intervals of 30 min. Each group consisted of 20 individuals on average.
All three serum parameters increased after the test meal reaching their peak between 60 and 90 min after the test meal. “ p < 0.05, * p < 0.01
and ° p < 0.001 as compared to C.
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Figure 2 Active TGF-β serum levels before and after a test meal. T2DM patients treated with metformin and sulfonylurea (S+M), insulin
glargine (G+M) or a DPP-4 inhibitor (D+M) as well as non-diabetic controls (C) received a standardized test meal. Over the course of 5 h, active
TGF-β serum levels were measured at 30 min intervals. Each group consisted of 20 individuals on average. (a) Basal active TGF-β serum levels
strongly depend on the pharmaceutical strategy. * p < 0.05, ** p < 0.01 and *** p < 0.001. (b) After the test meal, active TGF-β serum levels
dropped after having reached their peak about 60 min after the test meal and then normalized to baseline levels. “ p < 0.05 as compared to C.
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Table 2 Area under the curve (AUC) from −30 to 300 min
Area under the curve C S + M G + M D + M
TGF-β [ng/ml] 7014 9689 8047 4873
Glucose [mg/dl] 33961 51821 53402 44817
Insulin [pmol/l] 8268 16057 8922 9493
Proinsulin [pmol/l] 3165 9832 6294 4523
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strongly decreased in the control group and in the
T2DM patients treated with S+M or G+M. In all three
groups, active TGF-β serum levels dropped in the first
60 min after the test meal, and reached the initial base-
line levels at the end of the observation period. The ac-
tive TGF-β serum levels of T2DM patients treated with
D+M did not vary significantly throughout the observa-
tion period (Figure 2b).
To determine the total amount of active TGF-β over
the entire observation time, the area under curve (AUC)
was defined. The AUCs for active TGF-β, glucose, insu-
lin and pro-insulin are presented in Table 2. However,Figure 3 Correlation analysis between basal active TGF-β serum level
active TGF-β serum levels of T2DM patients treated with metformin and su
well as of non-diabetic controls (C) were correlated with basal (a) blood glno correlation between active TGF-β and basal glucose,
insulin or pro-insulin levels was observed (Figure 3a-c).
Discussion
TGF-β is involved in many cellular processes, e.g. the
modulation of the immune system and enhanced forma-
tion of extracellular matrix [8,9]. Increased matrix forma-
tion is one reason why TGF-β is regarded as a key player
in the development of fibrosis in many organs [10]. Espe-
cially in the kidneys, excessive matrix formation by
mesangial cells and interstitial fibroblasts contributes to
the manifestation of diabetic kidney disease [3]. A reduced
activation of TGF-β in the kidney may reduce the risk of
development of fibrosis. In the present study, we analyzed
serum levels of active TGF-β in patients with T2DM
treated according to different anti-diabetic therapies. So
far, little is known about the effect of different blood
glucose-lowering interventions on TGF-β. The fasting ac-
tive TGF-β serum levels were significantly higher in
T2DM patients treated with S+M in comparison to the
three other groups. The fasting active TGF-β serum levelss and fasting blood glucose, insulin and proinsulin levels. Basal
lfonylurea (S+M), insulin glargine (G+M) or a DPP-4 inhibitor (D+M) as
ucose levels, (b) insulin levels, and (c) proinsulin levels.
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of the non-diabetic controls. T2DM patients treated with
D+M even had significantly decreased fasting active TGF-
β serum levels comparable to those of the non-diabetic
controls. After the test meal, the active TGF-β serum
levels dropped for around one hour and increased again to
baseline levels during the following four hours. This de-
crease of TGF-β after the meal suggests a direct connec-
tion to insulin secretion. However, we were not able to
show a direct correlation between these two factors, pos-
sibly due to a timely shift in the response or the involve-
ment of more factors. As the insulin secretion occurs in a
physiologically biphasic and pulsatile manner [11], our
T2DM patients already exhibited a delayed and prolonged
insulin secretion when T2DM was diagnosed.
The three T2DM patient groups were commonly treated
with the biguanide metformin. As we observed signifi-
cantly different fasting active TGF-β serum levels between
the individual treatment groups, we suppose that metfor-
min does not directly affect the expression and activation
of TGF-β. This is supported by data demonstrating that
the treatment of mesangial cells with metformin does not
influence the glucose transport or the expression of fibro-
nectin and collagen at physiological conditions [12].
The sulfonylurea tolazamide significantly stimulates the
secretion of TGF-β1, and thus the synthesis and accumula-
tion of collagen and fibronectin in mesangial cells [12].
This supports our findings that T2DM patients treated
with S+M exhibit increased fasting active TGF-β serum
levels. However, it has been discussed recently that this
observation might be strongly glucose-dependent, as
mesangial cells exposed to different concentrations of glu-
cose and to the sulfonylurea glibenclamide exhibited an
increased expression of TGF-β only at high glucose con-
centrations [4,13,14]. In this setting, a 10-fold concentra-
tion of glibenclamide even inhibited collagen synthesis
[13,14].
In our study, T2DM patients receiving D+M had the
lowest fasting active TGF-β serum levels. This is sup-
ported by a study with 10-week-old db/db mice, where the
treatment with a DPP-4 inhibitor extenuated the expres-
sion of TGF-β1 and reduced myocardial fibrosis [15]. In
streptozotocin-induced diabetic rats, 24 weeks of treat-
ment with a DPP-4 inhibitor reduced the TGF-β1 expres-
sion. Thus, this inhibitor was reno-protective [16].
Remarkably, fasting active TGF-β serum levels in this
group were significantly lower compared to the non-
diabetic controls. For many bodily functions, a fine adjust-
ment of TGF-β expression and activation is necessary. A
complete abortion of the TGF-β activation, as observed in
our T2DM patients treated with D+M after the test meal,
might be critical. Nevertheless, the role of TGF-β in
T2DM must be investigated further, since it seems to sup-
press atherosclerosis in diabetic patients [17].Conclusions
Our study suggests that different blood glucose-lowering
pharmacological interventions have a significant impact
on the serum levels of pro-fibrotic active TGF-β. Treat-
ment with M+G as well as with M+D was superior to
the treatment with M+S in keeping low fasting active
TGF-β serum levels. However, further investigations will
be needed to clarify the clinical significance of TGF-β re-
garding the development of kidney fibrosis and its role
in suppressing atherosclerosis or other pathologies in pa-
tients with T2DM.
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